granular corneal dystrophy type I
diseaseOn this page
Also known as CDGG1classic GCDclassic granular corneal dystrophycorneal dystrophy granular typecorneal dystrophy Groenouw type Icorneal dystrophy punctate or nodularcorneal dystrophy, Groenouw type IGCD1GCDIgranular corneal dystrophy type 1Groenouw type I corneal dystrophy
Summary
granular corneal dystrophy type I (MONDO:0007377) is a disease caused by TGFBI (GenCC Definitive), with 1 cohort gene.
At a glance
- Prevalence: Unknown (Worldwide)
- Causal gene: TGFBI (GenCC Definitive)
- Cohort genes: 1
- ClinVar variants: 10
- Phenotypes (HPO): 10
Clinical features
Signs & symptoms
Clinical features (HPO)
10 HPO clinical features (Orphanet curated; top 10 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000531 | Corneal crystals | Very frequent (80-99%) |
| HP:0007881 | Central corneal dystrophy | Very frequent (80-99%) |
| HP:0000495 | Recurrent corneal erosions | Frequent (30-79%) |
| HP:0000505 | Visual impairment | Frequent (30-79%) |
| HP:0011493 | Central opacification of the cornea | Frequent (30-79%) |
| HP:0000613 | Photophobia | Occasional (5-29%) |
| HP:0007663 | Reduced visual acuity | Occasional (5-29%) |
| HP:0008039 | Subepithelial corneal opacities | Occasional (5-29%) |
| HP:0011495 | Abnormal corneal epithelium morphology | Occasional (5-29%) |
| HP:0200026 | Ocular pain | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | granular corneal dystrophy type I |
| Mondo ID | MONDO:0007377 |
| MeSH | C537304 |
| OMIM | 121900 |
| Orphanet | 98962 |
| DOID | DOID:0080530 |
| SNOMED CT | 419039007 |
| UMLS | C1641846 |
| MedGen | 351521 |
| GARD | 0009677 |
| Is cancer (heuristic) | no |
Also known as: CDGG1 · classic GCD · classic granular corneal dystrophy · corneal dystrophy granular type · corneal dystrophy Groenouw type I · corneal dystrophy punctate or nodular · corneal dystrophy, Groenouw type I · GCD1 · GCDI · granular corneal dystrophy type 1 · Groenouw type I corneal dystrophy
Data availability: 10 ClinVar variants · 3 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › epithelial-stromal TGFBI dystrophy › granular corneal dystrophy type I
Related subtypes (7): corneal granular dystrophy, epithelial basement membrane dystrophy, lattice corneal dystrophy type I, Thiel-Behnke corneal dystrophy, granular corneal dystrophy type II, Reis-Bucklers corneal dystrophy, corneal dystrophy, lattice type 3A
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
10 retrieved; paginated sample, class counts are floors:
3 uncertain significance, 3 conflicting classifications of pathogenicity, 2 pathogenic, 1 likely pathogenic, 1 pathogenic/likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 7866 | NM_000358.3(TGFBI):c.1663C>T (p.Arg555Trp) | TGFBI | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 7871 | NM_000358.3(TGFBI):c.1501C>A (p.Pro501Thr) | TGFBI | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 7873 | NM_000358.3(TGFBI):c.370C>A (p.Arg124Ser) | TGFBI | Pathogenic | criteria provided, single submitter |
| 1333310 | NM_000358.3(TGFBI):c.1855A>G (p.Met619Val) | TGFBI | Likely pathogenic | criteria provided, single submitter |
| 4279757 | NM_000358.3(TGFBI):c.1954G>C (p.Glu652Gln) | TGFBI | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 7878 | NM_000358.3(TGFBI):c.1998G>C (p.Arg666Ser) | TGFBI | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 904412 | NM_000358.3(TGFBI):c.895G>A (p.Asp299Asn) | TGFBI | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 225487 | NM_000358.3(TGFBI):c.1631A>G (p.Asn544Ser) | TGFBI | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 4533224 | NM_000358.3(TGFBI):c.459+6A>G | TGFBI | Uncertain significance | criteria provided, single submitter |
| 906736 | NM_000358.3(TGFBI):c.387G>C (p.Arg129Ser) | TGFBI | Uncertain significance | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 14 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| TGFBI | Definitive | Autosomal dominant | epithelial-stromal TGFBI dystrophy | 14 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| TGFBI | Orphanet:98956 | Epithelial basement membrane dystrophy |
| TGFBI | Orphanet:98960 | Thiel-Behnke corneal dystrophy |
| TGFBI | Orphanet:98961 | Reis-Bücklers corneal dystrophy |
| TGFBI | Orphanet:98962 | Granular corneal dystrophy type I |
| TGFBI | Orphanet:98963 | Granular corneal dystrophy type II |
| TGFBI | Orphanet:98964 | Lattice corneal dystrophy type I |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| TGFBI | HGNC:11771 | ENSG00000120708 | Q15582 | Transforming growth factor-beta-induced protein ig-h3 | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| TGFBI | Transforming growth factor-beta-induced protein ig-h3 | Plays a role in cell adhesion. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| TGFBI | Other/Unknown | no | FAS1_domain, EMI_domain, TGFBI/POSTN |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| amniotic fluid | 1 |
| pericardium | 1 |
| synovial joint | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| TGFBI | 278 | ubiquitous | marker | amniotic fluid, synovial joint, pericardium |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| TGFBI | 2,988 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| TGFBI | Q15582 | 10 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 2. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Amyloid fiber formation | 1 | 102.9× | 0.019 | TGFBI |
| Metabolism of proteins | 1 | 12.4× | 0.081 | TGFBI |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| negative regulation of cell adhesion | 1 | 383.0× | 0.012 | TGFBI |
| chondrocyte differentiation | 1 | 300.9× | 0.012 | TGFBI |
| extracellular matrix organization | 1 | 122.1× | 0.017 | TGFBI |
| cell population proliferation | 1 | 102.8× | 0.017 | TGFBI |
| visual perception | 1 | 79.5× | 0.018 | TGFBI |
| angiogenesis | 1 | 62.4× | 0.019 | TGFBI |
| cell adhesion | 1 | 37.5× | 0.027 | TGFBI |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| TGFBI | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| TGFBI | 1 | Binding:1 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | TGFBI |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| TGFBI | 1 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: TGFBI